Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression
The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some users react differently to the same antidepressant [19] while different antidepressants produce different effects [20].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [20]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“(Hamilton, 1960).”
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923 · cited 1×
“To determine if one drug acts faster than the other and/ or placebo in reducing the overall severity or specific symptomatic behaviors during this 2-week treatment period, the linear mixed model (Laird and Ware, 1982) was used to model the longitudinal change in each construct.”
MethodKupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 2×
“…approach (Katz et al, 1984), doctor ratings included the Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and…”
MethodThe Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · cited 1×
“…Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and Itil, 1974); nurse ratings: the Affective Disorder Rating Scale…”
BackgroundAn inventory for assessing different kinds of hostility.
Buss, A. H., & Durkee, A. (1957) · Journal of Consulting Psychology · doi:10.1037/h0046900 · Cited by 2,575 · cited 2×
“…(Murphy et al, 1980), NIMH Mood Scale (Raskin et al, 1969), Global Ward Behavior Scale (Raskin et al, 1969); patient self-reports included the Symptoms Checklist (SCL-90; Derogatis et al, 1974); NIMH Mood Scale (Raskin et al, 1969); and the Buss–Durkee Hostility Inventory (Buss and Durkee, 1957).”
MethodWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“This later behavioral effect of paroxetine may not be due to serotonin exclusively, but to sequential or direct interactions between serotonin and noradrenergic or even dopaminergic systems (Willner, 1997; Bonhomme and Esposito, 1998; Bourin et al, 2001).”
Background
Research works printed but not linked: 3
- Guy W (1976). Early clinical drug evaluation program (ECDEU). In: Assessment Manual of Psychopharmacology. Department of Health, Education and Welfare: Rockville MD.
- Murphy DL, Pickar D, Alterman JS (1980). Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EJ, Sudilovsky A, Gershon S (eds) Quantitative Techniques for the Evaluation of the Behavior of Psychiatric Patients. Marcel-Decker: New York, 355–392.
- Spitzer RL, Williams JBW (1983). Instruction manual For the Structured Clinical Interview for DSM III (SCID), Revision. Biometrics Research Department, M.Y. State Psychiatric Institute: New York.
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“While preliminary data were suggestive (Dubini et al., 1997; Katz et al., 2004), an analysis of two RCTs of reboxetine against fluoxetine found no reproducible difference in degree of improvement of different symptoms (Nelson et al.”
ResultDopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
“Indeed, when the treatment is effective, it can take weeks to get a therapeutic effect (Katz et al., 2004).”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…strongly suggesting that a true drug response can be observed within the fi rst 14 days of treatment (Nierenberg et al. 2000; Szegedi et al. 2003; Katz et al. 2004; Posternak and Zimmerman 2005; Papakostas et al. 2006; Taylor et al. 2006; Stassen et al. 2007; Henkel et al. 2009; Hennings et…”
BackgroundMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
“Moreover, the full clinical benefit of these traditional antidepressants is only achieved following weeks to months of treatment (4).”
BackgroundTaylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Cryan, J. F., Page, M. E., & Lucki, I. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0093-5 · Cited by 321
“There is also evidence that some behavioral changes observed in patients early on in clinical treatments may predict or at least be relevant to positive therapeutic outcome later (Harmer et al. 2003; Katz et al. 2004).”
BackgroundSchiffer, F., Johnston, A. L., Ravichandran, C., Polcari, A., Teicher, M. H., Webb, R. H., & Hamblin, M. R. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-46 · Cited by 317
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
“The findings by Katz and colleagues described above suggested that early behavioral changes taking place during the first two weeks of treatment could predict subsequent long-term outcome [23,28,30].”
BackgroundInfluentialMorilak, D. A., & Frazer, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004080 · Cited by 252
Self-citationA role for AMPA receptors in mood disorders
Alt, A., Nisenbaum, E. S., Bleakman, D., & Witkin, J. M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.022 · Cited by 238
“[20] Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al.”
BackgroundKETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS
Abdallah, C. G., Adams, T. G., Kelmendi, B., Esterlis, I., Sanacora, G., & Krystal, J. H. (2016) · Depression and Anxiety · doi:10.1002/da.22501 · Cited by 206
“[3] Moreover, it takes weeks or even months to gain the full therapeutic effects of traditional antidepressants.[4] There is a critical unmet need for antidepressants with a rapid onset of action, particularly in patients who do not respond to traditional antidepressants.”
Machado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195
Identifying fast-onset antidepressants using rodent models
Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 182
Mood disorders: Regulation by metabotropic glutamate receptors
Pilc, A., Chaki, S., Nowak, G., & Witkin, J. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.021 · Cited by 163
“[50] Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al.”
BackgroundNew targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Fournier, N. M., & Duman, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.022 · Cited by 155
Li, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 170
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 162
“This rapid antidepressant effect is in contrast to traditional monoamine-based antidepressants that take weeks to months to exert their full antidepressant effect (Katz et al., 2004), with response rates between 40% and 50% (Trivedi et al.”
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
“This is consistent with clinical reports that current antidepressant treatments require at least two weeks for symptom improvement and six to eight weeks of chronic administration before a full therapeutic response is observed [55, 56].”
O'Sullivan, J. B., Ryan, K. M., Curtin, N. M., Harkin, A., & Connor, T. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570800967x · Cited by 146
“These drugs increase noradrenaline availability by blockading the reuptake of noradrenaline, and are used clinically for the treatment of attention deficit hyperactivity disorder and depression, respectively (Katz et al. 2004 ; Kelsey et al. 2004).”
BackgroundWhat should animal models of depression model?
Frazer, A., & Morilak, D. A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.006 · Cited by 137
Self-citationRapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah, C. G., Fasula, M., Kelmendi, B., Sanacora, G., & Ostroff, R. (2012) · The Journal of ECT · doi:10.1097/yct.0b013e31824f8296 · Cited by 123
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Tadić, A., Helmreich, I., Mergl, R., Hautzinger, M., Kohnen, R., Henkel, V., & Hegerl, U. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.04.014 · Cited by 117
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 116
Oxytocin Involvement in SSRI-Induced Delayed Ejaculation: A Review of Animal Studies
de Jong, T. R., Veening, J. G., Olivier, B., & Waldinger, M. D. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00394.x · Cited by 108
Suicidal ideation and the subjective aspects of depression
Keilp, J. G., Grunebaum, M. F., Gorlyn, M., LeBlanc, S., Burke, A. K., Galfalvy, H., Oquendo, M. A., & Mann, J. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.045 · Cited by 100
“The association of suicidal ideation with the mood disturbance and self-blame components of depressive disorder is relevant for clinical care because these symptoms can be among the last to respond temporally during a course of treatment with some antidepressants (Katz et al., 2004; Papakostas et al., 2007).”
BackgroundSchwieler, L., Samuelsson, M., Frye, M. A., Bhat, M., Schuppe-Koistinen, I., Jungholm, O., Johansson, A. G., Landén, M., Sellgren, C. M., & Erhardt, S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0517-7 · Cited by 106
Prins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
“The same distinction can be made in humans, where drug-induced alterations in the serotonergic system have been associated with anxiolytic effects and changes in the noradrenergic systems with reducing psychomotor symptoms [184].”
BackgroundSartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
Witkin, J. M., Overshiner, C. D., Li, X., Catlow, J. T., Wishart, G. N., Schober, D. A., Heinz, B. A., Nikolayev, A., Tolstikov, V., Anderson, W. H., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216804 · Cited by 110
“Generally safe and efficacious, these antidepressants do not relieve all symptoms of depression, and they require several weeks of dosing for full treatment efficacy to emerge (Katz et al., 2004).”
BackgroundBenedetti, F., Dallaspezia, S., Fulgosi, M. C., Barbini, B., Colombo, C., & Smeraldi, E. (2007) · Chronobiology International · doi:10.1080/07420520701649455 · Cited by 97
“This is consistent with the wide literature that reports psychomotor retardation, usually being worse in the morning, as one of the first symptoms Phase Advance: A Correlate of Antidepressant Response 933 targeted by antidepressant treatment (e.g., Katz et al., 2004).”
ResultThe Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects
Dell’Osso, B., Palazzo, M. C., Oldani, L., & Altamura, A. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00217.x · Cited by 96
“In an interesting study analyzing the profile of action of Desipramine versus the SSRI Paroxetine in hospitalized veterans, Desipramine was more effective in reducing motor retardation and hostility whereas Paroxetine initially improved anxiety and hostility [34].”
BackgroundLapiz, M. D. S., Bondi, C. O., & Morilak, D. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301235 · Cited by 95
Taliaz, D., Spinrad, A., Barzilay, R., Barnett-Itzhaki, Z., Averbuch, D., Teltsh, O., Schurr, R., Darki-Morag, S., & Lerer, B. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01488-3 · Cited by 93
“…at multiple time points be a shortcoming, considering that it was repeatedly shown that trajectories of antidepressant response are commonly not linear [52 – 56], with some studies stating that early therapeutic effects may be better predictors of a subsequent positive long-term outcome [55 – 57].”
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 95
Yohn, S. E., Collins, S. L., Contreras-Mora, H. M., Errante, E. L., Rowland, M. A., Correa, M., & Salamone, J. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.188 · Cited by 100
“Of course, this does not mean that other transmitters, such as 5-HT, are not involved in other aspects of depression (e.g. mood dysfunction, rumination, anxiety, hostility; see Katz et al, 2004; Carr and Lucki 2011; Bell et al, 2013).”
Genetic Regulation of Behavioral and Neuronal Responses to Fluoxetine
Miller, B. H., Schultz, L. E., Gulati, A. D., Cameron, M. D., & Pletcher, M. T. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301497 · Cited by 93
“…by which antidepressants act is poorly understood: although antidepressants produce elevation of synaptic serotonin levels within minutes of administration (Ross and Renyi, 1975; Bel and Artigas, 1992; Malagie et al, 1995), measurable clinical response may not occur for weeks (Katz et al, 2004).”
BackgroundNordgreen, J., Munsterhjelm, C., Aae, F., Popova, A., Boysen, P., Ranheim, B., Heinonen, M., Raszplewicz, J., Piepponen, P. T., Lervik, A., et al. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.07.013 · Cited by 93
“However, when improvement is measured as a gradual return of some (but not all) functions, the therapeutic lag is shorter and improved mood and reduced motor retardation may be seen within two weeks after initiating treatment with a selective noradrenaline reuptake inhibitor [87].”
Backgroundvan Wingen, G. A., Tendolkar, I., Urner, M., van Marle, H. J. F., Denys, D. A. J. P., Verkes, R., & Fernández, G. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.022 · Cited by 88
“We investigated a two week administration because of its well-known association with the onset of the clinical response (Katz et al., 2004), which could lead to different results than an acute dose (Klomp et al., 2013) or a seven day administration (McCabe and Mishor, 2011).”
MethodResultYohn, S. E., Errante, E. L., Rosenbloom-Snow, A., Somerville, M., Rowland, M. A., Tokarski, K., Zafar, N., Correa, M., & Salamone, J. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.018 · Cited by 88
van Calker, D., Zobel, I., Dykierek, P., Deimel, C. M., Kech, S., Lieb, K., Berger, T., & Schramm, E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.07.023 · Cited by 84
“As shown previously for other antidepressants (Katz et al., 2004; Nierenberg et al., 2000; Szegedi et al., 2003) these early improvements were a very sensitive predictor of later stable response or remission.”
BackgroundInfluentialWitkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 72
Gelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Khan, A., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1001 · Cited by 79
Self-citationThe influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
“Another limitation of currently available antidepressants is that their clinical effects take more time to reach their full therapeutic potential (for instance, the mean onset for paroxetine is 13 days) [29].”
BackgroundYohn, S., López-Cruz, L., Hutson, P., Correa, M., & Salamone, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4176-7 · Cited by 68
Accelerating response to antidepressant treatment in depression: A review and clinical suggestions
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.001 · Cited by 80
Paroxetine versus other anti-depressive agents for depression
Purgato, M., Papola, D., Gastaldon, C., Trespidi, C., Magni, L. R., Rizzo, C., Furukawa, T. A., Watanabe, N., Cipriani, A., & Barbui, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006531.pub2 · Cited by 71
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., Tadić, A., & Lieb, K. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.003 · Cited by 73
Rincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 80
“~40– 60% of patients fail to achieve remission) and slow onset of therapeutic effects in the patients that do respond, in that weeks or even months of treatment are required (Akil et al., 2018; Gaynes et al., 2009; Katz et al., 2004).”
BackgroundFatigue as a core symptom in major depressive disorder: overview and the role of bupropion
Pae, C.-U., Lim, H.-K., Han, C., Patkar, A. A., Steffens, D. C., Masand, P. S., & Lee, C. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1251 · Cited by 73
Tadić, A., Wagner, S., Schlicht, K. F., Peetz, D., Borysenko, L., Dreimüller, N., Hiemke, C., & Lieb, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.011 · Cited by 82
“A substantial body of evidence from many retrospective studies incorporating in total more than 12,000 patients and virtually all groups of antidepressants (Henkel et al., 2009; Hennings et al., 2009; Katz et al., 2004; Nierenberg et al., 2000; Stassen et al., 2007; Szegedi et al., 2003, 2009; Tadić et al., 2010a) sho…”
Neuropsychological changes and treatment response in severe depression
Douglas, K. M., Porter, R. J., Knight, R. G., & Maruff, P. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080713 · Cited by 67
Barbon, A., Caracciolo, L., Orlandi, C., Musazzi, L., Mallei, A., Via, L. L., Bonini, D., Mora, C., Tardito, D., Gennarelli, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.013 · Cited by 74
“Classical antidepressants, despite acting immediately on the synaptic levels of serotonin and noradrenaline, exert their clinical effect mainly after 2–6 weeks of administration (Katz et al., 2004; McIntyre, 2010; Nakajima et al., 2010; Taylor et al., 2006; Trivedi et al., 2006).”
BackgroundCunha, M. P., Budni, J., Ludka, F. K., Pazini, F. L., Rosa, J. M., Oliveira‐Giacomelli, Á., Lopes, M. W., Tasca, C. I., Leal, R. B., & Rodrigues, A. L. S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9192-4 · Cited by 69
Serotonergic and Noradrenergic Modulation of Emotion Processing by Single Dose Antidepressants
Brühl, A. B., Kaffenberger, T., & Herwig, U. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.159 · Cited by 73
Dreimüller, N., Schlicht, K. F., Wagner, S., Peetz, D., Borysenko, L., Hiemke, C., Lieb, K., & Tadić, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.017 · Cited by 75
“Taking into account the large amount of data suggesting that a true drug response can be observed in the first 10e14 days (Henkel et al., 2009; Nierenberg et al., 2000; Katz et al., 2004; Posternak and Zimmerman, 2005; Papakostas et al., 2006; Taylor et al., 2006; Stassen et al., 2007; Szegedi et al., 2003, 2009; Tadi…”
BackgroundKorb, A. S., Hunter, A. M., Cook, I. A., & Leuchter, A. F. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.12.007 · Cited by 59
“…of pretreatment brain activity, numerous reports also have demonstrated a strong relationship between eventual response and symptom improvement in the first 2 weeks of treatment (Szegedi et al., 2003; Katz et al., 2004; Papakostas et al., 2007; Stassen et al., 2007; Szegedi et al., 2009).”
BackgroundLi, B., Suemaru, K., Cui, R., & Araki, H. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.01.032 · Cited by 62
Mallinckrodt, C. H., Prakash, A., Houston, J. P., Swindle, R., Detke, M. J., & Fava, M. (2007) · Neuropsychobiology · doi:10.1159/000111537 · Cited by 59
Self-citationBondi, C. O., Barrera, G., Lapiz, M. D. S., Bedard, T., Mahan, A., & Morilak, D. A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.11.015 · Cited by 56
Gardier, A. M. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283243fcd · Cited by 54
“In particular, while they produce a relatively fast blockade of the 5-HT transporter (SERT) in vitro, the onset of an appreciable antidepressant-like effect in vivo is slow, taking several weeks to occur in humans (Katz et al., 2004) as well as in animals (Dulawa et al., 2004).”
BackgroundZhao, Z., Zhang, H.-T., Bootzin, E., Millan, M. J., & O'Donnell, J. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.183 · Cited by 55
“…inhibitors (NRIs), and serotonin–norepinephrine reuptake inhibitors (SNRIs), this results from inhibition of the norepinephrine or serotonin transporters (NET, SERT), which clear the transmitters from the synapse (Beyer et al, 2002; Katz et al, 2004; Morilak and Frazer, 2004; White et al, 2005).”
Dunlop, B. W., Crits-Christoph, P., Evans, D. L., Hirschowitz, J., Solvason, H. B., Rickels, K., Garlow, S. J., Gallop, R. J., & Ninan, P. T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815abefb · Cited by 56
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies
Brannan, S. K., Mallinckrodt, C. H., Detke, M. J., Watkin, J. G., & Tollefson, G. D. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.05.005 · Cited by 54
Self-citationTrajectories of individual symptoms in remitters versus non-remitters with depression.
Sakurai, H., Uchida, H., Abe, T., Nakajima, S., Suzuki, T., Pollock, B., Sato, Y., & Mimura, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.035 · Cited by 53
Benmansour, S., Deltheil, T., Piotrowski, J. P., Nicolas, L., Repérant, C., Gardier, A. M., Frazer, A., & David, D. J. P. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.048 · Cited by 60
“Whereas these drugs produce relatively rapid blockade of monoamine transporters in vitro, the onset of an appreciable clinical effect on mood is slower (Katz et al., 2004).”
BackgroundSelf-citationTadić, A., Wachtlin, D., Berger, T., Braus, D. F., van Calker, D., Dahmen, N., Dreimüller, N., Engel, A., Gorbulev, S., Helmreich, I., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.003 · Cited by 50
“For the risk group of patients without improvement in the first two weeks of treatment, remission and response rates range between 4–14 and 11–19 percent (Henkel et al., 2009; Hennings et al., 2009; Katz et al., 2004; Nierenberg et al., 2000; Papakostas et al., 2006; Posternak and Zimmerman, 2005; Stassen et al., 2007…”
BackgroundMechanisms of the placebo effect in pain and psychiatric disorders
Holmes, R. D., Tiwari, A. K., & Kennedy, J. L. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.15 · Cited by 57
Bai, T., Wei, Q., Zu, M., Xie, W., Wang, J., Ji, G., Yu, F., Tian, Y., & Wang, K. (2018) · Human Brain Mapping · doi:10.1002/hbm.24387 · Cited by 51
Munsterhjelm, C., Nordgreen, J., Aae, F., Heinonen, M., Valros, A., & Janczak, A. M. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.09.018 · Cited by 56
Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Zaytseva, A., Bouckova, E., Wiles, M. J., Wustrau, M. H., Schmidt, I. G., Mendez-Vazquez, H., Khatri, L., & Kim, S. (2023) · eLife · doi:10.7554/elife.86022 · Cited by 48
“However, it can take weeks or months for traditional antidepressants to fully manifest their therapeutic advantages (Katz et al., 2004).”
BackgroundKetamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y.-K. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 42
Zhao, Z., Baros, A. M., Zhang, H., Bluhm, M. D. L., Bondi, C. O., Morilak, D. A., & O’Donnell, J. M. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.45 · Cited by 52
Shelton, R. C., Prakash, A., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Robinson, M. J., & Detke, M. J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01444.x · Cited by 49
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44
Katz, M. M., Bowden, C. L., & Frazer, A. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.08.011 · Cited by 45
“(Katz et al., 2004a) The CDS results generated a followup study which directly compared two targeted drugs, a SSRI, paroxetine, a selective norepinephrine (SNRI), desipramine (DMI), and a placebo control group.”
BackgroundMethodResultInfluentialSelf-citationKang, S. Y., Park, E., Park, W., Kim, H. J., Jeong, D.-Y., Jung, M. E., Song, K., Lee, S., Seo, H. J., Kim, M. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.093 · Cited by 44
Lee, L. H.-W., Shui, G., Farooqui, A. A., Wenk, M. R., Tan, C.-H., & Ong, W.-Y. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570900995x · Cited by 43
“Elevations of neurotransmitter levels in the brain are almost instantaneous but elevation of mood is delayed until at least 2 wk later (Katz et al. 2004 ; Mitchell, 2006).”
BackgroundGibson, K., Cartwright, C., & Read, J. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0844-3 · Cited by 43
Is depression an inflammatory condition? A review of available evidence.
Hashmi, A. M., Butt, Z., & Umair, M. (2013) · PubMed · Cited by 54
Piras, G., Piludu, M. A., Giorgi, O., & Corda, M. G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3205-7 · Cited by 42
“The potential predictive value of such behavioral patterns may therefore provide useful guidelines for designing novel and more efficient therapies of depression (Katz et al. 2004).”
Garakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328301a74c · Cited by 39
“However, there has been recent evidence that the ‘delayed-onset hypothesis’ may be inaccurate, and that there is a noticeable response within the first week of initiation of treatment (Katz et al., 2004; Posternak and Zimmerman, 2005; Taylor et al., 2006).”
BackgroundGe, K., Bai, Z., Wang, J., Li, Z., Gao, F., Liu, S., Zhang, L., Gao, F., & Xie, C. (2025) · Advanced Materials · doi:10.1002/adma.202418872 · Cited by 42
Nakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., Takeuchi, H., Abe, T., Kashima, H., & Mimura, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.008 · Cited by 40
Podkowa, K., Podkowa, A., Sałat, K., Lenda, T., Pilc, A., & Pałucha-Poniewiera, A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.031 · Cited by 42
Seo, H. J., Park, E., Kim, M. J., Kang, S. Y., Lee, S., Kim, H. J., Lee, K. N., Jung, M. E., Lee, M., Kim, M.-S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200682b · Cited by 47
Suicidal ideation declines with improvement in the subjective symptoms of major depression
Keilp, J. G., Ellis, S. P., Gorlyn, M., Burke, A. K., Oquendo, M. A., Mann, J. J., & Grunebaum, M. F. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.018 · Cited by 39
Antidepressant effects of ketamine and ECT: A pilot comparison
Sharma, R. K., Kulkarni, G., Kumar, C. N., Arumugham, S. S., Venkataramaiah, S., Mehta, U. M., Mitra, S., Thanki, M. V., & Thirthalli, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.066 · Cited by 41
Lovick, T. A. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113490327 · Cited by 41
“Typically around 10 days of continuous treatment with SSRIs is required before patients show a clinical response (Katz et al., 2004).”
BackgroundRojas, P. S., Fritsch, R., Rojas, R., Jara, P., & Fiedler, J. L. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.04.032 · Cited by 40
“, 1984), there is a large body of evidence suggesting that a true response to an antidepressant can be observed within the first 14 days of treatment (Nierenberg et al., 2000; Katz et al., 2004; Posternak and Zimmerman, 2005; Papakostas et al., 2006; Taylor et al., 2006; Stassen et al., 2007; Tadic et al., 2010a).”
BackgroundResultRotolo, R. A., Kalaba, P., Dragačević, V., Presby, R. E., Neri, J., Robertson, E., Yang, J.-H., Correa, M., Bakulev, V. A., Volkova, N. N., et al. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05625-6 · Cited by 37
Subchronic duloxetine administration alters the extended amygdala circuitry in healthy individuals
van Marle, H. J. F., Tendolkar, I., Urner, M., Verkes, R. J., Fernández, G., & van Wingen, G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.12.051 · Cited by 33
“Duloxetine and placebo were administered for two weeks each (with a washout period in between), which corresponds to the onset of the clinical response (Katz et al., 2004).”
BackgroundRapid acting antidepressants in the mTOR pathway: Current evidence
Athira, K. V., Mohan, A. S., & Chakravarty, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.022 · Cited by 37
Kudlow, P. A., Cha, D. S., & McLntyre, R. S. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205701211 · Cited by 32
“ca 782 W La Revue canadienne de psychiatrie, vol 57, no 12, décembre 2012 CanJPsychiatry 2012;57(12):782–788”
BackgroundDimethyltryptamine: Endogenous Role and Therapeutic Potential
Rodrigues, A. V., Almeida, F., & Vieira‐Coelho, M. A. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1602291 · Cited by 38
Valentine, G., Dow, A., Banasr, M., Pittman, B., & Duman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1239-z · Cited by 32
“For example, in clinically depressed subjects, DMI has a faster initial onset of therapeutic effects and selectively on motor retardation, as compared to the slower initial effect of the SSRI paroxetine on anxiety measures (Katz et al. 2004; 2006).”
Metadata
- Authors
- Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Dallas VA Medical Center (US)
- Harbor–UCLA Medical Center (US)
- Corresponding author
- Frazer, Alan
- ORCID
- Frazer, Alan
- Venue
- Neuropsychopharmacology
- Published
- 2003-11-19
- Volume
- 29
- Issue
- 3
- Pages
- 566-579
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2319982487
- Cited by
- 252
- References
- 72
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 13 · 2014: 10 · 2013: 20 · 2012: 7
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressant onset of action, depression, paroxetine, desipramine, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, placebo response, motor retardation, depressive mood, anxiety, treatment response prediction
- MeSH terms
- Adult, Affect, Aged, Analysis of Variance, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Desipramine, Double-Blind Method, Female, Humans, Male, Middle Aged, Motor Activity, Time Factors, Placebo Effect, Chi-Square Distribution, Logistic Models, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.